BMS' Opdivo Gets CHMP Backing For Expanded European Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Use for previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression, is recommended by EMA Committee for Medicinal Products for Human Use.
You may also be interested in...
Deal Watch: Exelixis Teams With Ipsen For Ex-US Commercialization Of RCC Candidate
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.
AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC
Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.
PD-1 Round-Up: Bristol's Lead Grows, But Field Could Soon See Major Change
Leading sponsors of PD-1/L1 checkpoint inhibitors looked back on a string of successes and ahead toward the future for combinations with a wide range of other targets during full-year earnings calls.